{"id":73967,"date":"2021-11-06T01:01:25","date_gmt":"2021-11-06T06:01:25","guid":{"rendered":"https:\/\/milesfortis.com\/?p=73967"},"modified":"2021-11-06T01:01:25","modified_gmt":"2021-11-06T06:01:25","slug":"73967","status":"publish","type":"post","link":"https:\/\/milesfortis.com\/?p=73967","title":{"rendered":""},"content":{"rendered":"<p>This is a <a href=\"https:\/\/www.webmd.com\/hiv-aids\/what-are-protease-inhibitors\">protease inhibitor<\/a>, which is a class of drugs that were originally developed to fight the AIDS virus and have been adapted to other virus caused illnesses.<\/p>\n<hr \/>\n<p><a href=\"https:\/\/www.upi.com\/Top_News\/US\/2021\/11\/05\/pfizer-covid-pill-paxlovid\/9781636113852\/\" target=\"_blank\" rel=\"noopener\">Pfizer Says COVID-19 Pill Almost 90% Effective Preventing Severe Illness, Death<\/a><\/p>\n<p>Pharma company Pfizer announced on Friday that its experimental, antiviral COVID-19 treatment pill Paxlovid showed during testing that it&#8217;s almost 90% effective in preventing hospitalization and death in high-risk patients.<\/p>\n<p>The company said when combined with a low dose of ritonavir and taken within five days of the onset of symptoms, it cut severe illness and death attributed to the coronavirus by 89%.<\/p>\n<p>&#8220;Today&#8217;s news is a real game-changer in the global efforts to halt the devastation of this pandemic,&#8221; Pfizer CEO Albert Bourla said in a statement.<\/p>\n<p>&#8220;These data suggest that our oral antiviral candidate if approved or authorized by regulatory authorities has the potential to save patients&#8217; lives, reduce the severity of COVID-19 infections, and eliminate up to 9 out of 10 hospitalizations.&#8221;<\/p>\n<p>Pfizer said it&#8217;s now requesting emergency use authorization from the Food and Drug Administration, which would allow it to be distributed nationwide. If authorized, Pfizer&#8217;s would be the first COVID-19 treatment tablet on the market.<\/p>\n<p>Paxlovid joins a coronavirus treatment drug from Merck, molnupiravir, in the federal review category. Regulators are presently assessing molnupiravir for emergency authorization, and British regulators authorized the Merck drug on Thursday.<\/p>\n<p>&#8220;We have remained laser-focused on the science and fulfilling our responsibility to help healthcare systems and institutions around the world while ensuring equitable and broad access to people everywhere,&#8221; Bourla added.<\/p>\n<p>Pfizer said its double-blind study examined a group of non-hospitalized, high-risk adults with COVID-19. In the trial, just six of more than 600 volunteers were hospitalized after taking Paxlovid &#8212; compared to 41 of 612 who were given a placebo.<\/p>\n<p>Pfizer said no volunteer who took Paxlovid during the trial died, compared to 10 from the placebo group who did.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This is a protease inhibitor, which is a class of drugs that were originally developed to fight the AIDS virus and have been adapted to other virus caused illnesses. Pfizer Says COVID-19 Pill Almost 90% Effective Preventing Severe Illness, Death Pharma company Pfizer announced on Friday that its experimental, antiviral COVID-19 treatment pill Paxlovid showed &hellip; <a href=\"https:\/\/milesfortis.com\/?p=73967\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[],"class_list":["post-73967","post","type-post","status-publish","format-standard","hentry","category-health-medicine"],"_links":{"self":[{"href":"https:\/\/milesfortis.com\/index.php?rest_route=\/wp\/v2\/posts\/73967","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/milesfortis.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/milesfortis.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/milesfortis.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/milesfortis.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=73967"}],"version-history":[{"count":1,"href":"https:\/\/milesfortis.com\/index.php?rest_route=\/wp\/v2\/posts\/73967\/revisions"}],"predecessor-version":[{"id":73968,"href":"https:\/\/milesfortis.com\/index.php?rest_route=\/wp\/v2\/posts\/73967\/revisions\/73968"}],"wp:attachment":[{"href":"https:\/\/milesfortis.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=73967"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/milesfortis.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=73967"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/milesfortis.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=73967"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}